Key points are not available for this paper at this time.
Glioblastoma (GBM) is one of the most aggressive cancers, with poor overall survival (OS) and few effective therapies. 1 Even as the understanding of the molecular underpinnings of GBM has increased substantially over the past decade, there has been minimal development of new drugs that leverage this information. Clearly, the therapeutic development ecosystem for GBM is not producing optimal results. There are many possible reasons for the lack of progress in developing new therapies for GBM, but there is little evidence to suggest what the main drivers are. Complex biology, the presence of a blood-brain barrier, lack of sufficient investment, and others have all been cited. 1 While improvement in the way that patients with GBM feel, function, and survive depends most directly on the discovery
Vanderbeek et al. (Thu,) studied this question.